用于筛查献血者的HIV-1/2与HTLV-I/II联合检测方法的评估

Evaluation of a combined HIV-1/2 and HTLV-I/II assay for screening blood donors.

作者信息

Flanagan P, McAlpine L, Ramskill S J, Smith A G, Eglin R, Parry J V, Mortimer P P

机构信息

Yorkshire Blood Transfusion Service, Leeds, UK.

出版信息

Vox Sang. 1995;68(4):220-4. doi: 10.1111/j.1423-0410.1995.tb02576.x.

DOI:10.1111/j.1423-0410.1995.tb02576.x

PMID:7660640

Abstract

A combined immunoassay for the simultaneous detection of antibodies to HIV-1/2 and HTLV-I/II (Bioelisa, Launch Diagnostics) has been evaluated to determine its suitability for routine use in blood screening. 84,222 donations were tested from 76,452 donors. One HIV- and 1 HTLV-1-positive donor were identified. The specificity was 99.7%, and the sensitivity for anti-HIV-1, anti-HIV-2, and anti-HTLV-1 on 173 positive sera was 100%; 2 of 25 anti-HTLV-II-positive sera were non-reactive. Although the specificity of the assay is not as high as that of HIV-1/2 kits currently in UK transfusion use, the information gained about donor HTLV antibody status makes the test an attractive alternative to them.

摘要

已对一种用于同时检测HIV-1/2和HTLV-I/II抗体的联合免疫测定法（Bioelisa，Launch Diagnostics）进行了评估，以确定其在血液筛查常规使用中的适用性。对76452名献血者的84222份献血样本进行了检测。鉴定出1名HIV阳性和1名HTLV-1阳性献血者。特异性为99.7%，在173份阳性血清上，抗HIV-1、抗HIV-2和抗HTLV-1的敏感性为100%；25份抗HTLV-II阳性血清中有2份无反应性。尽管该测定法的特异性不如目前英国输血中使用的HIV-1/2试剂盒高，但所获得的关于献血者HTLV抗体状态的信息使该检测成为它们有吸引力的替代方法。